|
|
|
| Study on medication rule of traditional Chinese medicine and pharmacy prescription in the treatment of membranous nephropathy based on data mining |
| LIU Weiwei1 LENG Wei2 YANG Zhaotian2 WANG Huanjing2 WANG Ning1 DU Zhifeng3 |
1.The First Clinical Medical College, Shaanxi University of Chinese Medicine, Shaanxi Province, Xianyang 712000, China;
2.the Second Department of Nephropathy, Affiliated Hospital of Shaanxi University of Chinese Medicine, Shaanxi Province, Xianyang 712000, China; 3.Academic School Inheritance Studio of Shaanxi Du’s Kidney Disease, Yumao Hospital, Shaanxi Province, Xianyang 712000, China |
|
|
|
Abstract Objective To study the medication rule of traditional Chinese medicine and pharmacy prescription in the treatment of membranous nephropathy based on data mining technology. Methods All literatures on the application of traditional Chinese medicine and pharmacy in the treatment of membranous nephropathy were searched from CNKI, Wanfang Data and VIP from the inception to October 2020. The search title, subject or key words were “membranous nephropathy” or “idiopathic membranous nephropathy” and “traditional Chinese medicine, Chinese materia medica, traditional Chinese medicine and pharmacy” or “integrated Chinese and Western medicine”. The traditional Chinese medicine inheritance assist platform was used to conduct statistics, association rule analysis and cluster analysis on the data. Results Through statistics, 125 prescriptions that met the standards were obtained, involving 230 Chinese materia medicas in total, and 23 Chinese materia medicas that were used with frequency ≥ 20. According to the classification of the included drugs, the traditional Chinese medicine and pharmacy in the treatment of membranous nephropathy mainly consists of drugs to replenish deficiency, drugs to diuresis and diffusing dampness, drugs to promoting blood circulation for removing blood stasis, etc. There were 20 drug combinations with frequency > 30. Among them, milkvetch root, Sichuan lovage rhizome, Indian bread, Chinese yam, largehead atractylodes rhizome, danshen root, Chinese angelica, earthworm and tangshen appeared many times in the prescription. Cluster analysis obtained 20 core drug combinations and 10 potential new prescriptions. Conclusion The etiology and pathogenesis of this disease is blood stasis due to qi deficiency, and the disease is asthenia in origin and asthenia in superficiality. The treatment is based on benefiting qi for activating blood circulation, and the clinical use of drugs to replenish deficiency, drugs to diuresis and diffusing dampness, drugs to promoting blood circulation for removing blood stasis.
|
|
|
|
|
|
[1] Cai Q，Hendricks AR. Membranous nephropathy：A ten-year journey of discoveries [J]. Semin Diagn Pathol，2020， 37（3）：116-120.
[2] Ronco P，Debiec H. Molecular Pathogenesis of Membranous Nephropathy [J]. Annu Rev Pathol，2020，15：287-313.
[3] 付平，李鑫睿.特发性膜性肾病诊疗进展[J].中国中西医结合肾病杂志，2020，21（7）：565-567.
[4] 谢琼虹，陈瑞颖，薛骏，等.原发性膜性肾病（PMN）的诊治进展[J].复旦学报：医学版，2020，47（4）：615-621.
[5] 张晓凤，程小红，权浩浩，等.原发性膜性肾病诊治研究进展[J].中国中西医结合肾病杂志，2020，21（5）：459-461.
[6] 佘阿敏，盛梅笑.膜性肾病的中医药研究进展[J].长春中医药大学学报，2016，32（1）：205-206.
[7] 杨丽影，杨巧芳，牛丽丽.中医治疗膜性肾病的临床进展[J].中华中医药学刊，2017，35（10）：2512-2514.
[8] Hosohata K. Can Focal Segmental Glomerulosclerosis Be Differentiated From Minimal Change Nephrotic Syndrome Using Biomarkers? [J]. Am J Med Sci，2018，355（4）：305-306.
[9] 张琳，杨洪涛.杨洪涛中医药治疗膜性肾病经验[J].辽宁中医杂志，2018，45（7）：1370-1372.
[10] 朱国福.中药学[M].北京：清华大学出版社，2012.
[11] 卢朋，李健，唐仕欢，等.中医传承辅助系统软件开发与应用[J].中国实验方剂学杂志，2012，18（9）：1-4.
[12] 聂莉芳，徐建龙.运用补法治疗慢性肾脏病的经验[J].中国中西医结合肾病杂志，2020，21（5）：377-380.
[13] 王要强，吴瑞，管传涛，等.基于数据挖掘技术的慢性肾脏病中医症候规律研究[J].世界中医药，2020，15（24）：3870-3875.
[14] 甘安平，吴满满，张文，等.关于特发性膜性肾病中医病因病机的论述[J].中国现代医生，2021，59（9）：139-142， 146.
[15] 王文蔚，贾成祥，王用书.论“新病入络”与“久病入络”[J].中华中医药杂志，2018，33（3）：1030-1033.
[16] 李平，谢院生，童安荣，等.肾脏病蛋白尿的中西医结合诊断及治疗[J].中国中西医结合肾病杂志，2020，21（5）：468-470.
[17] 谭海丽，周少婷，黄国东，等.特发性膜性肾病中医辨证论治现状研究[J].新中医，2018，50（4）：36-39.
[18] 陈翀，孙伟.基于肠肾轴概念从肾-肺-大肠轴谈孙伟教授治疗慢性肾脏病的经验[J].西部中医药，2019，32（5）：74-77.
[19] 王林，杨志华，杨康，等.基于数据挖掘分析杨洪涛教授治疗膜性肾病用药规律[J].中国医药导报，2021，18（7）：122-125.
[20] 白艳洁，王文凤，杨霓芝.杨霓芝教授治疗原发性肾病综合征临床经验介绍[J].中国中西医结合肾病杂志，2017， 18（2）：100-101.
[21] 郑启艳，孙鲁英，金化男，等.益气活血法治疗特发性膜性肾病的Meta分析[J].中国中药杂志，2017，42（18）：3613-3622.
[22] 刘童童，丁英钧.赵玉庸治疗膜性肾病经验[J].中华中医药杂志，2016，31（10）：4064-4066.
[23] 黄一珊，张帅星，刘伟敬，等.黄芪在肾脏病中的应用及不良反应[J].中国中西医结合肾病杂志，2020，21（6）：550-552.
[24] 杨柳，张王宁，刘月涛，等.基于网络药理学的黄芪治疗肾病综合征的机制研究[J].中草药，2019，50（8）：1828-1837.
[25] 郑晓珂，于洋，周静，等.白术各化学拆分组分及其配伍对大鼠肾病综合征的影响[J].中药新药与临床药理，2016，27（4）：467-474.
[26] 罗粤铭，翁衡，黄馨怡，等.基于数据挖掘的肾系水肿茯苓运用研究[J].世界科学技术-中医药现代化，2019，21（10）：2159-2167.
[27] 苏醒，徐建龙，包蓓艳.黄芪当归汤辅助治疗慢性肾脏病（3期～4期）的临床研究[J].中华中医药学刊，2015， 33（2）：495-497.
[28] 王元真，赵汉儒，林丽娟.黄芪当归合剂联合他克莫司对难治性肾病综合征患者免疫功能及肾功能的影响[J].上海中医药杂志，2019，53（6）：58-60，74.
[29] 夏平，张露，刘琼，等.基于“肾虚湿瘀”理论治疗慢性肾脏病的核心方药分析[J].世界科学技术-中医药现代化，2019，21（6）：1075-1084. |
|
|
|
